ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

GILBERTO DE CASTRO Jr, FATIMA SOLANGE PASINI, SHEILA APARECIDA COELHO SIQUEIRA, ALBERTO ROSSETTI FERRAZ, ROSANGELA CORREA VILLAR, IGOR MOYSÉS LONGO SNITCOVSKY and MIRIAM HATSUE HONDA FEDERICO

1Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Av. Dr. Arnaldo 251, São Paulo SP 01246000; 2Disciplina de Oncologia, Laboratório de Investigação Médica LIM-24, Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo 455, São Paulo SP 01246003; 3Pathology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar 155, São Paulo; 4Head and Neck Surgery Service, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar 255, São Paulo SP 05403900; 5Radiation Oncology Service, Instituto de Radiologia-InRad, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar 255, São Paulo SP 05403001, Brazil

Received October 13, 2010; Accepted November 29, 2010

DOI: 10.3892/or.2011.1133

Abstract. Adjuvant cisplatin-based chemoradiation improves survival in HNSCC patients presenting with risk features. ERCC1 (excision repair cross-complementation group 1) is associated with resistance to chemo- and radiation therapy and may have a prognostic value in HNSCC patients. Here we studied ERCC1 expression and the polymorphism T19007C as prognostic markers in these patients. This is a retrospective and translational analysis, where ERCC1 protein expression was evaluated by immunohistochemistry, using an H-score, and mRNA expression was determined by RT-PCR. T19007C genotypes were detected by PCR-RFLP carried out using DNA template extracted from normal lymph nodes. A high H-score was seen in 32 patients (54%), who presented better 5-year overall survival (5-y OS: 50% vs. 18%, HR 0.43, p=0.026). Fifteen out of 45 patients (33%), with high mRNA expression, presented better 5-year overall survival (OS) (86% vs. 30%, HR 0.26, p=0.052). No OS difference was detected among T19007C genotypes. High H-score and mRNA expression remained significant as favorable prognostic factors in a multivariate analysis. Collectively, our results suggest that high ERCC1 expression seems to be associated with better OS rates in HNSCC patients submitted to adjuvant cisplatin-based chemoradiation.

Introduction

Head and neck cancer accounts for around 645,000 new cases each year, worldwide, 75% of them with stage III-IV disease, causing more than 350,000 deaths yearly (1). Adjuvant cisplatin-based concurrent chemoradiation improves progression-free survival in patients diagnosed with head and neck squamous cell carcinoma (HNSCC) presenting with risk features, submitted to surgery with curative intent, and OS gains are seen in some subgroups (2-5). A hurdle in the interpretation of these trials is patient heterogeneity, in spite of attempts to control for prognostic factors.

Cisplatin cytotoxicity is based on the formation of interstrand and intrastrand cross-links, caused by adducts in the DNA structure, blocking nucleotide replication and transcription. Nucleotide excision repair (NER) is one of the molecular mechanisms involved in DNA repair and mediates cell sensitivity to cisplatin. It comprised more than 30 distinct proteins that recognize DNA damage, incise the lesion, and resynthesize and ligate the repair patch (6). The excision repair cross-complementation group 1 (ERCC1) protein plays a rate-limiting role in the NER pathway: it forms a complex with Xeroderma Pigmentosum Complementation Group F and this complex is involved in the 5' excision of the damaged DNA (7).

As expected, lower ERCC1 expression, either evaluated as mRNA expression or protein levels, correlates with better outcomes in several cancers after platinum-based therapy.
including HNSCC, suggesting that ERCC1 expression could have a role in predicting sensitivity to cisplatin-based chemotherapy (8-12). In contrast to this effect, a low expression of ERCC1 per se may at the same time be associated with the accumulation of DNA mutations and results in a more aggressive tumor phenotype (13-16). Thus, ERCC1 expression may have itself a dual effect in terms of prognosis. In the HNSCC patients treated by both surgery and adjuvant cisplatin-based chemoradiation, the predominant effect of ERCC1 remains still unclear.

In addition, some single nucleotide polymorphisms (SNPs) of ERCC1 have been described, some of them are thought to be functional. Particularly interesting is the SNP T19007C:rs11615 in codon 118, which has been associated with response rate and/or overall survival in patients diagnosed with colorectal cancer (17,18). In other tumor types, including HNSCC, however, this association was not consistently demonstrated (19-22).

We studied ERCC1 expression at protein and mRNA levels and the role of the ERCC1 SNP T19007C as prognostic markers in HNSCC patients presenting with risk features treated with surgery and adjuvant chemoradiation.

Materials and methods

Patient population. In this retrospective analysis, eligibility requirements were: histologically-proven SCC of oral cavity, oropharynx, hypopharynx, or larynx; patients had to be submitted to radical surgery with curative intent, and considered to be candidates to adjuvant chemoradiation, due to the presence of high- or intermediate-risk factors (extra-capsular spread in positive lymph nodes, surgical margins microscopically involved, stage III/IV disease, positive lymph nodes at levels IV or V in patients with tumors arising from oropharynx or oral cavity, lymphovascular embolisms, perineural infiltration); they had to be treated with at least one cycle of chemotherapy; no distant metastasis; no relapsed disease after surgery; no other malignancy; no other therapy before or after surgery. Adjuvant chemoradiation consisted of 60-70 Gy, conventionally delivered (one daily fraction of 2 Gy), 5 times a week, concurrently to cisplatin 100 mg/m2, intravenously, on days 1, 22 and 43. The study protocol was approved by the local institutional ethics committee.

Immunohistochemical analysis for ERCC1. Fifty-nine formalin-fixed, paraffin-embedded tissue blocks were available for immunohistochemical analysis. A standardized immunohistochemistry protocol was used. Briefly, 5-μm thick tissue sections were deparaffinized, rehydrated and slides were soaked in 6% H2O2, 5 times, 5 min each. After, they were exposed to citrate buffer 0.01 M, pH 6.0 in a pressure cooker for 2.5 min for antigen retrieval. Tumor sections were then incubated with the murine primary antibody anti-ERCC1 (antibody Ab-2, clone 8F1, NeoMarkers, Fremont, CA, USA) diluted in 1% albumin/PBS diluents, overnight at 4°C in a humid chamber for 18 h. Slides were then incubated with the secondary antibody solution conjugated with a polymer (Novolink, Novocastra, Bannockburn, IL, USA) for 30 min at 37°C. The chromogenic substrate diaminobenzidine 60 mg/100 ml in PBS and H2O2 was then applied to cover the tissue sections for 3-5 min at 37°C. Slides were counterstained with Mayer’s hematoxylin, rinsed with water, and then dehydrated. Positive and negative external controls were used.

Tumor staining was assessed by a trained pathologist (SACS) who had no knowledge of patients’ clinical data, and microscopic analysis was done using the H-score as previously described (8,23). ERCC1 tumor (nuclei) staining intensity was graded on a scale of 0-3, using adjacent non-malignant cells as a reference (intensity grade, 2). The percentage of positive tumor cells was evaluated in 1000 tumor cells and a proportion score was attributed: 0 if 0%, 0.1 if 1-9%, 0.5 if 10-49%, and 1.0 if 50% or more. This proportion score was then multiplied by the staining intensity to obtain a final semiquantitative H-score. The optimal cut-off value for differentiation of patient’s categories (high or low expression) was defined by ROC analysis (see below).

Isolation of nucleic acids. Genomic DNA and total RNA were extracted from formalin-fixed, paraffin-embedded tissue blocks of tumor-free lymph nodes and primary tumor, respectively, by using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Austin, TX, USA), according to the manufacturer’s instructions. For each sample, 3-4 10-20-μm thick block sections were deparaffinized in xylene at 50°C for 3 min, and the pellet was washed with ethanol twice. Each sample was submitted to digestion with protease, and for RNA or DNA isolation, samples were incubated with DNase or RNase, respectively. After successive washings, nucleic acids were eluted in nuclease-free water at 95°C.

Quantitative real-time reverse transcriptase-PCR. As the RNA extracted from formalin-fixed tissues is likely to be degraded, it was planned to analyze small amplicons. RNA integrity was assessed through microfluidic analysis in the Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany) and its concentration was determined by measuring its absorbance at 260 nm using the NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to determine ERCC1 mRNA expression, normalized by using 18S fraction of ribosomal RNA expression as internal reference. Two independent assays were carried out and it was accepted a difference <1.0 between the threshold cycles. One sample was randomly chosen to be analyzed in all assays as a reference and a negative control was also used. For cDNA synthesis, 1 μg of total RNA was reverse transcribed in a solution of 20 μl containing 100 ng of random hexamer primers, 20 μM dNTPs mixture, 50 mM Tris-HCl, 75 mM KCl, 1.5 mM MgCl2, 5 mM DTT and 100 U SuperScript III reverse transcriptase (Invitrogen, Life Technologies, CA, USA) at 50°C for one hour and the reaction was terminated at 70°C for 15 min.

For each qRT-PCR, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 200 μM each dNTP, 5% dimethyl sulphoxide, 100 nM sense and antisense oligonucleotides for each gene, 1.0 nM MgCl2, 1.5 times the volume of SYBR-Green, 1.5 U of Platinum Taq DNA Polymerase (Invitrogen), 100 ng
and 1 ng of cDNA for ERCC1 and 18S determination, respectively, to a final volume of 20 μl, were used. After 40 cycles, the denaturation curves were obtained in the range of 72 to 95˚C. The oligonucleotides were designed with the Primer 3 software (http://frodo.wi.mit.edu/prime3/), version 0.4.0, and purchased from Integrated DNA Technologies Inc. (Coralville, IO, USA): ERCC1 sense 5'-GACTATGTCGTG GGCCAGAG-3', ERCC1 antisense 5'-GTAGCGGAGGCT GAGGAAC-3'; 18S sense 5'-CGCCGCTAGAGGTGAAAT TC-3', 18S antisense 5'-TTGGCAAATGCTTTCGCTC-3'. The product of the each qRT-PCR was analyzed with the Rotor-Gene 6 software, version 6.0 (Corbett Research, Sydney, Australia), and the relative expression ratio of ERCC1 was calculated as proposed by Pfaffl (24). The deviation of control minus sample of the target (ERCC1) or reference (18S) gene transcripts were calculated according to the derived cycle threshold values (Ct). The optimal cut-off value for differentiation of the patient categories (high or low expression) was defined by ROC analysis (see below). The qRT-PCR efficiencies of ERCC1 and 18S transcripts were 2.1 and 1.99, respectively.

Genotyping of the ERCC1 codon 118. The ERCC1 codon 118 SNP was detected by PCR-restriction fragment length polymorphism (RFLP). Genomic DNA (50 ng) was amplified in a 50-μl mixture of 200 μM of each dNTP, 2.5 U Taq DNA polymerase, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂ and 0.2 μM sense 5'-GCAGAGCTCACCTGAGGAAC-3' and 0.2 μM antisense 5'-GAGGTGCAAGAAGAGGTGGAGA-3'. PCR products, after being digested by the BsrDI restriction enzyme (New England Biolabs, Beverly, MA, USA) at 60˚C, 16 h, were separated on 3% ethidium bromide-stained agarose gel. The RFLP analysis of the resultant 208-bp fragment led to C/C (208 bp), C/T (208, 128 and 80 bp) and T/T (128 and 80 bp) genotypes. Gel images were obtained using the ImageMaster VDS (Amersham Biosciences AB, Uppsala, Sweden).

Statistical methods. Disease-free survival (DFS) was defined as the time from the end of radiation therapy to any type of progression (loco-regional or distant, or second primary tumor). Overall survival (OS) was defined as the time from the end of radiation therapy to death from any cause. Kaplan-Meier curves were calculated and compared using log-rank test. The end of follow-up was March 31, 2009. Patients who were alive or had not progressed at the last follow-up were censored at that time.

Univariate and multivariate stepwise procedure Cox regression analyses were used to assess the association between potential prognostic factors and survival. Factors with p-values <0.1 in univariate analysis were included in multivariate analysis. Exploratory analyses were performed using Fisher's exact test or χ², where appropriate. Continuous variables were compared by t-test. Spearman's rank correlation coefficient was calculated to assess the relationship involving discrete variables. The optimal cut-off value for differentiation of the patient categories (positive or negative) was defined by ROC analysis with the best sensitivity and specificity for each evaluable variable. All statistical tests were two-sided with significance defined as p<0.05. Analyses were performed using the MedCalc software (MedCalc, Mariakerk, Belgium), version 9.3.2.0.

Results

Patient characteristics and clinical outcomes. Sixty-nine patients were identified from 1998 to 2007 (Table I). Median age was 56 years and 81% were male. Oral cavity was the most common primary site (41%). Forty patients (58%) were classified as high-risk and the remaining 29 patients (42%) were classified as intermediate-risk (3). Extracapsular spread in positive lymph nodes was identified in 27 patients (39%) and surgical margins were microscopically involved in 18 patients (26%). The median time elapsed from surgery to adjuvant chemoradiation was 2.9 months (range, 1.3-10.6 months) and the median duration of radiation therapy was

<table>
<thead>
<tr>
<th>Table I. Patient characteristics.</th>
<th>No. of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>56 (81)</td>
</tr>
<tr>
<td>Female</td>
<td>13 (19)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>56</td>
</tr>
<tr>
<td>Range</td>
<td>25-79</td>
</tr>
<tr>
<td>Primary tumor site</td>
<td></td>
</tr>
<tr>
<td>Oral cavity</td>
<td>28 (41)</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>8 (12)</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>11 (16)</td>
</tr>
<tr>
<td>Larynx</td>
<td>22 (32)</td>
</tr>
<tr>
<td>T stage</td>
<td></td>
</tr>
<tr>
<td>pT1-pT2</td>
<td>15 (22)</td>
</tr>
<tr>
<td>pT3-pT4</td>
<td>54 (78)</td>
</tr>
<tr>
<td>N stage</td>
<td></td>
</tr>
<tr>
<td>pN0-pN1</td>
<td>29 (42)</td>
</tr>
<tr>
<td>pN2-pT3</td>
<td>40 (58)</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>24 (35)</td>
</tr>
<tr>
<td>2</td>
<td>36 (52)</td>
</tr>
<tr>
<td>3</td>
<td>9 (13)</td>
</tr>
<tr>
<td>Resection-margin status</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>18 (26)</td>
</tr>
<tr>
<td>Negative</td>
<td>51 (74)</td>
</tr>
<tr>
<td>Positive nodes</td>
<td></td>
</tr>
<tr>
<td>0-1</td>
<td>26 (38)</td>
</tr>
<tr>
<td>2 or more</td>
<td>43 (62)</td>
</tr>
<tr>
<td>Extracapsular spread</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>27 (39)</td>
</tr>
<tr>
<td>Negative</td>
<td>42 (61)</td>
</tr>
</tbody>
</table>
56 days (range, 37-134 days). The median number of administered chemotherapy cycles was 3, and the median overall treatment time (from surgery to the end of adjuvant chemoradiation) was 21 weeks (range, 13-54 weeks).

The median follow-up time for living patients was 47 months (range, 6-91 months), being 39 patients alive and 29 disease-free. Eleven loco-regional and 7 distant relapses were observed, 10 patients were diagnosed with a secondary primary tumor and 30 patients died, 22 as a consequence of disease progression. The 5-year OS rate was 40% and the median OS was 52.5 months. The 5-year DFS rate was 31%, and the median DFS was 36.6 months. No significant difference in OS was detected in terms of gender, stage, grading and pathological risk features.

**Immunohistochemical analysis of ERCC1.** The expression of ERCC1 by immunohistochemistry was evaluated in 59 patients. Tissue blocks were not available for 10 patients. Representative examples of tumor expression of H-scores are shown in Fig. 1. The median H-score was 2. The optimum cut-off value for discrimination of dead and living patients was calculated as 1.5 (sensitivity 61%, specificity 68%, area under the ROC curve 0.63, 95% CI 0.49-0.75, p=0.081), and those 32 patients (54%) whose tumors presented H-score >1.5 were classified as having high H-scores. These high H-score patients presented better 5-year OS rate in comparison to those with low H-scores (50% vs. 18%, HR 0.43, 95% CI 0.20-0.90, p=0.026), as shown in Fig. 2. Among patients classified as high-risk, no difference in terms of OS was observed, regarding H-score: 48.7 months (high H-score) vs. 23.5 months (low H-score; HR 0.56, 95% CI 0.23-1.40, p=0.219).

**ERCC1 mRNA expression.** ERCC1 mRNA expression was determined in 45 patients. Tissue blocks were not available for 10 patients, isolated RNA was degraded in 10 patients and the small amount of isolated RNA was not possible to be analyzed in the four remaining patients. The deviation of $C_t$ ($\Delta C_t$) of ERCC1 gene had mean value of $-3.05 \pm 3.10$, and $\Delta C_t$ of 18S gene had mean value of $-4.59 \pm 4.09$. The median of relative ERCC1 mRNA expression was 2.58 (range, 0.25-19.26). The optimum cut-off value for discrimination of dead and living patients was calculated as 3.1 (sensitivity 89%, specificity 48%, area under the ROC curve 0.58, 95% CI 0.43-0.73, p=0.335), and those 15 patients (33%) whose tumors presented normalized ERCC1 mRNA expression >3.1 were classified as having high expression. These patients with high ERCC1 mRNA expression presented better 5-year OS rate in comparison to those with low expression (86% vs. 31%,
DNA was degraded in 7 patients and in the 3 remaining. Tissue blocks were not available for 10 patients, isolated respectively. Representative genotyping results are shown in Fig. 4. Genotyping of the ERCC1 codon 118 was performed in 49 patients, and the frequencies of C/C, C/T and T/T were 37, 39 and 24%, respectively. Representative genotyping results are shown in Fig. 4. Tissue blocks were not available for 10 patients, isolated DNA was degraded in 7 patients and in the 3 remaining patients, the small amount of isolated DNA was not possible to be analyzed. This polymorphism followed the Hardy-Weinberg’s equilibrium among patients ($\chi^2=2.242$, $p=0.326$).

ERCC1 mRNA expression was not different between patients presenting with the C/C, or C/T, T/T genotypes ($p=0.758$). No significant association was found between age, gender, stage, grading and pathological risk features and ERCC1 codon 118 genotypes. No difference was detected among C/C, C/T and T/T genotypes in terms of 5-year OS rates (45, 46, 46%; $p=0.808$).

**Discussion**

We studied the expression of ERCC1 at protein and mRNA levels, as well as the SNP T19007C of ERCC1 as prognostic markers in patients with high or intermediate risk HNSCC treated with surgery and adjuvant chemoradiation with cisplatin. We found that patients with high expression of ERCC1, either at the protein or mRNA levels, had better prognosis. In disagreement with our data, previous published data obtained in 96 HNSCC patients have shown worse OS in patients whose tumors were positive for ERCC1, as determined by immunohistochemistry, and treated with induction chemotherapy (cisplatin and 5-fluorouracil), followed by definitive radiotherapy in responding patients (8). A similar deleterious effect for high ERCC1 expression was shown in 45 HNSCC patients treated with cisplatin-based chemoradiation (25), and also among 34 HNSCC treated by induction chemotherapy (cisplatin and docetaxel) followed by concurrent cisplatin-based chemoradiation (26). More recently, two other studies have shown no influence on response rate or survival for ERCC1 expression in HNSCC patients treated by cisplatin-based induction chemotherapy, followed by radiation therapy or radical surgery, or concurrent cisplatin, radiotherapy and cetuximab (27,28). On the other hand, studies done in two other tobacco-related cancers, namely non-small cell lung cancer and pancreatic adenocarcinoma, treated by surgery alone, indicate that ERCC1 positivity may implicate in a favorable prognosis, which is in line with our results (13,14,29).

Thus, the prognostic value of ERCC1 may be dependent on the treatment modality. In surgically treated HNSCC patients, the high expression of ERCC1 would be associated with better prognosis and an opposite effect would be seen in those patients treated with (chemo-)radiation, preceded or no by induction chemotherapy. The underlying mechanisms could related to the dual nature of ERCC1, to favor less mutagenesis and be associated with less aggressive tumors or to counteract cisplatin induced cell death (30). This interpretation, as commented by Gazdar (15), is compatible with the results of a large biomarker study in non-small cell lung cancer (10). Increased ERCC1 expression was also shown to be correlated with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer (31). The clinical scenario of the latter study is analogous to ours, an aggressive tumor primarily treated by surgery, with a modest benefit for adjuvant therapy.

Two additional issues may confound the interpretation of studies addressing ERCC1 as a biomarker. First, the inconsistencies of ERCC1 expression as determined by H-score in regard to prognosis, related to its subjective
nature for quantification, inter- and intraobserver variability, and different cut-off values. Indeed, the accuracy of the anti-ERCC1 antibody here used may be another issue of concern (32). Second, since the relationship of ERCC1 mRNA level and protein expression may be variable, the method of ERCC1 detection may be critical. In this regard, we were reassured by our results, which showed that ERCC1 was prognostic both at mRNA and protein levels. An additional strength of our work was the demonstration of the feasibility of ERCC1 mRNA expression and SNP genotyping using archived formalin-fixed tissue and not frozen samples, which are not routinely available. In terms of biomarkers validation, an increasing number of studies are showing consistent results of quantification of target genes in formalin-fixed, paraffin-embedded archived tissues. Those successful determinations of mRNA expression are being achieved by using well developed extraction kits and methodologies (33).

The 5-year OS and DFS rates we observed (39 and 30%, respectively) are inferior to those described in phase III trials (2,3). Possible explanations are the small percentage of patients (12%) with primary tumor located in the oropharynx, a high frequency of microscopically involved surgical margins (26%), and above all, a very long median overall treatment time (21 weeks) from surgery to the end of chemoradiation.

Our results suggest that T19007C SNP in the ERCC1 gene does not influence OS in our patients, in contrast to others, which found an association with response to platinum-based chemotherapy and survival in esophageal cancer, colorectal cancer, ovarian cancer and non-small cell lung cancer patients (17,34-36). A proposed mechanism is that T19007C SNP may decrease ERCC1 mRNA stability and consequently, protein expression. In prostate cancer, however, considerable interindividual differences in ERCC1 mRNA expression was seen among 376 patients, which could only partially be attributed to genetic (SNP) variation but could also be modified by factors such as plasma levels of antioxidants (37). To evaluate several polymorphic variants related with a specific activity, such as DNA-repair, seems interesting in the individual level. As reported by Quintela-Fandino et al., the presence of polymorphic variants in DNA-repair genes are powerful prognostic factors and predictive of response to cisplatin in HNSCC patients (38).

We conclude that high immunohistochemical expression of ERCC1 protein and high ERCC1 mRNA expression seem to be associated with better prognosis in HNSCC patients submitted to surgery and adjuvant cisplatin-based chemotherapy. ERCC1 expression may be used to better stratify HNSCC patients in clinical trials evaluating adjuvant cisplatin-based chemoradiation, however, a prospective validation is necessary.

Acknowledgements

This study was presented in the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, 4-8 June 2010. The authors are indebted to Bruno Ferenc Papp Cadima for his assistance in qRT-PCR assays, and also to Aleyvore Talans for editing assistance.

References


